Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.


Player Avatar JorgeAura (< 20) Submitted: 12/6/2012 7:13:34 PM : Outperform Start Price: $26.50 DVAX Score: +12.33

Heplisav data adequately demonstrated immunogenicity. Company with good future.

Featured Broker Partners